European/US Analyst: Immuron Moving to Forefront i

MELBOURNE, Australia, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (the “Company”) wishes to advise investors that European and US-based Life Sciences Research and Analyst firm Van Leeuwenhoeck Institute (“VLI”), has released a Research Note Report on the Company and its R&D programs, which primarily focuses on the Company’s NASH assets and comparing them to other recent NASH product acquisitions by large Pharma companies.

VLI provides institutional investors and other professional investors with independent, un-biased research on the real value of innovative Life Sciences companies.

A copy of the Research Note can be viewed on the Company website at:

http://immuron.com/assets/Van-Leeuwenhoeck-In...n-2017.pdf .

About Van Leeuwenhoeck Institute:

Van Leeuwenhoeck Institute (VLI) provides institutional investors and other professional investors with independent, un-biased research on the real value of innovative Life Sciences companies. Many institutional and individual investors will not invest in companies lacking independent third-party research coverage, yet few investment banks cover this sector because it requires dedicated expertise.

In spite of the lack of quality knowledge on an industry-wide basis, there is increased demand for life science-specific market research as investors are seeking information about leading companies in the sector in order to make well-informed investment decisions.

Immuron Limited has engaged VLI to provide the Company with logistical support services in support of potential European road shows.  

For more information visit: http://www.leeuwenhoeck.com/

About Immuron:

Immuron Limited (ASX:IMC) (OTCQB:IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases.  Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle.  The Company currently markets and sells Travelan® for the prevention of Travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH.  These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

For more information visit: http://www.immuron.com/

Forward-Looking Statements:

Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.

Company Contact: Thomas Liquard Chief Executive Officer AUS Ph: +61 (0)3 9824 5254 thomasliquard@immuron.com Immuron Media Relations: John Beveridge Monsoon Communications AUS Ph: +61 3 9620 3333 johnb@monsoon.com.au